.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,596,756

« Back to Dashboard
Patent 6,596,756 protects CYMBALTA and is included in one NDA. There have been two Paragraph IV challenges on Cymbalta. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for CYMBALTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in fourteen countries.

Summary for Patent: 6,596,756

Title: Treatment of fibromyalgia
Abstract:A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.
Inventor(s): Goldstein; David Joel (Indianapolis, IN), Iyengar; Smriti (Carmel, IN), Simmons; Rosa Marie Ademe (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/786,836
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 6th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-001Aug 3, 2004RXNo6,596,756*PED► subscribeY
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-002Aug 3, 2004RXNo6,596,756*PED► subscribeY
Lilly
CYMBALTA
duloxetine hydrochloride
CAPSULE, DELAYED REL PELLETS;ORAL021427-004Aug 3, 2004RXYes6,596,756*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,596,756

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 31 989Sep 09, 1999
PCT Information
PCT FiledSeptember 10, 1999PCT Application Number:PCT/US99/20986
PCT Publication Date:March 23, 2000PCT Publication Number: WO00/15223

International Patent Family for Patent: 6,596,756

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria449603► subscribe
Australia1197200► subscribe
Australia746887► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc